HBM Holdings files list of directors, board committee memberships and disclosure-responsible managementPUBT·10 hours ago02142-1.45%
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive DirectorsUnusual Whales·10 hours ago02142-1.45%
HBM Holdings names CFO Youchen Chen executive director amid board changesPUBT·10 hours ago02142-1.45%
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based StrategyPR Newswire·10 hours ago02142-1.45%
HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionPUBT·10 hours agoAMGN-0.76%02142-1.45%
Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?Simplywall·2 days ago, 12:36 PM02142-1.45%
HBM Holdings to Join Hang Seng Composite Index, Aiming to Boost Liquidity and Investor ReachTip Ranks·Aug 23 at 07:38 PM02142-1.45%
Weekly Recap | HBM HOLDINGS-B +7.51%, HBM7004 trial gets green lightWeekly Review·Aug 21 at 11:03 PM02142-1.45%
05:02 ETHarbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumorsprnewswire·Aug 18 at 04:03 AM02142-1.45%
HBM gets China NMPA clearance to start HBM7004 trial in advanced solid tumorsPUBT·Aug 18 at 04:02 AM02142-1.45%
HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced?Simplywall·Aug 9 at 06:31 AM02142-1.45%01099-1.92%
Harbour BioMed names Bob Zhang president of metabolic disease franchisePUBT·Aug 6 at 03:11 AM02142-1.45%
Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?Simplywall·Jul 28 at 02:13 PM02142-1.45%01099-1.92%
